Shanghai, China, November 14, 2022 – In the recent 2022 Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM), Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, was named “TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs.”
This year, more than 30,000 innovative companies and organizations were considered as part of the stringent selection process. The 20 finals were then determined by Shanghai Biomedical Industry Association and Yiyun Technology. The inclusion of Asieris on the list of “TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs” reflects the industry’s recognition of Asieris’ innovation capabilities.
Since its founding in 2010, Asieris has been committed to its mission of “improving human health and helping people live more dignified lives” and has been an industry leader in the field of genitourinary medicine R&D. Leveraging its expertise, Asieris has gained significant market insights into unmet clinical needs, and has actively built innovative solutions for integrated diagnosis and treatment. Currently, there are 12 projects in its development pipeline, correlating to 9 major innovative products. Among them, 2 core products, Vesique™ (APL-1202) and Cevira®(APL-1702), target the unmet global therapeutic gaps in bladder cancer and cervical precancerous lesions. Three studies relating to these products are in Phase III or undergoing pivotal clinical trials. Moving forward, the company will continue to strengthen its efforts in the genitourinary tumor treatment area and steadily advance its various R&D pipelines to deliver innovative solutions to benefit more patients worldwide.
About Asieris
Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health and help people live more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs and adopts a forward-looking approach to product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
